Opyl Ltd. (AU:OPL) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Opyl Ltd. has developed TrialKey, an AI-driven platform that boasts a 92%+ accuracy rate for predicting clinical trial success, aimed at reducing the high failure rate of biotech investments. With annual investments of US$80B across thousands of trials, TrialKey offers a data-driven approach to enhancing trial design. The platform sees significant market potential in Australia’s robust pharmaceutical and clinical research sectors, with a total addressable market of over $328 million for its reports.
For further insights into AU:OPL stock, check out TipRanks’ Stock Analysis page.